Increasing Cancer Epidemic Driving Growth In The Oligonucleotide Therapy Market Emerges as a Core Driver of the Oligonucleotide Therapy Market in 2025

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

Oligonucleotide Therapy Market Size Growth Forecast: What to Expect by 2025?
The market size for oligonucleotide therapy has experienced swift expansion in the past couple of years. It is projected to surge from $5.55 billion in 2024 to $6.18 billion in 2025, increasing at a compound annual growth rate (CAGR) of 11.4%. This robust growth during the historic period can be credited to an increase in research and development investment, entrance of pioneering therapies to the market, emergence of gene editing methods, early therapeutic breakthroughs, and the unveiling of RNAi and antisense oligonucleotide.

How Will the Oligonucleotide Therapy Market Size Evolve and Grow by 2029?
The market for oligonucleotide therapy is projected to expand significantly in the upcoming years, reaching a valuation of $9.82 billion in 2029 with a 12.3% compound annual growth rate (CAGR). This growth in the forecasted period can primarily be linked to increased investments in research and development, increased market penetration globally, expansion in the therapeutic area, modifications in disease strategies, and adjustments in regulations. Key trends expected during the forecasted period encompass personalized treatments, improvements in delivery systems, advancements in RNA interference (RNAI), innovations in antisense oligonucleotide, and the incorporation of gene editing techniques.

View the full report here:
https://www.thebusinessresearchcompany.com/report/oligonucleotides-therapy-global-market-report

What Drivers Are Propelling the Growth of Oligonucleotide Therapy Market Forward?
The global increase in cancer cases is predicted to enhance the oligonucleotide therapy market's expansion during the forecasted timeframe. For example, the American Cancer Society stated in January 2022 that an estimated 1.9 million fresh cancer diagnoses and 609,360 cancer-related fatalities in the United States are expected, translating to approximately 1,670 deaths per day. The four types of cancer most prevalent globally are lung, prostate, bowel, and female breast cancer, making up 43% of all the new cancer cases. The global surge in cancer incidence rates is expected to stimulate the demand for the oligonucleotide therapy market in the upcoming years.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3398&type=smp

Which Emerging Trends Are Transforming the Oligonucleotide Therapy Market in 2025?
Companies involved in the oligonucleotide therapy market are currently implementing research and development initiatives to improve the design of their therapies, with the aim of minimizing patient side effects. These improved, cutting-edge oligonucleotides enable more precision in treatment methods and can be engineered to selectively target any gene while ensuring minimal side effects. They also facilitate targeting of specific sequences in patients which lead to uncommon conditions. Notably, in April 2023, the FDA granted approval for Qalsody, a type of antisense oligonucleotide (ASO), for the use in treating patients suffering from amyotrophic lateral sclerosis (ALS) related to a mutation in the superoxide dismutase 1 (SOD1) gene. Qalsody operates by targeting the SOD1 mRNA with the goal of decreasing the production of SOD1 protein.

What Are the Key Segments in the Oligonucleotide Therapy Market?
The oligonucleotide therapy market covered in this report is segmented -

1) By Type: Antisense Oligonucleotide, Aptamer, Other Types
2) By Application: Infectious Diseases, Oncology, Neurodegenerative Disorders, Cardiovascular Diseases, Kidney Diseases, Other End-User
3) By End User: Hospitals, Research Institutes

Subsegments:
1) By Antisense Oligonucleotide: RNA-Targeted Antisense Oligonucleotides, DNA-Targeted Antisense Oligonucleotides, Chemically Modified Antisense Oligonucleotides
2) By Aptamer: DNA Aptamers, RNA Aptamers, Small Molecule Aptamers
3) By Other Types: siRNA (Small Interfering RNA), miRNA (Micro RNA), DNAzyme And Ribozymes, Synthetic Oligonucleotides For Gene Editing

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=3398&type=smp

Who Are the Key Players Shaping the Oligonucleotide Therapy Market's Competitive Landscape?
Major companies operating in the oligonucleotide therapy market include Pfizer Inc., Merck & Co. Inc., GlaxoSmithKline plc, Gilead Sciences Inc., BioNTech SE, Moderna Inc., Biogen Inc., Jazz Pharmaceuticals plc, QIAGEN Company, Alnylam Pharmaceuticals Inc., Sarepta Therapeutics Inc., Ionis Pharmaceuticals Inc., Akcea Therapeutics Inc., Arrowhead Pharmaceuticals Inc., Dicerna Pharmaceuticals Inc., SomaGenics Inc., Wave Life Sciences Ltd., Exicure Inc., Avidity Biosciences Inc., Miragen Therapeutics Inc., ProQR Therapeutics NV, Regulus Therapeutics Inc., Kastle Therapeutics LLC, Santaris Pharma A/S, InteRNA Technologies B.V., Dynacure S.A., Arcturus Therapeutics Holdings Inc., Intellia Therapeutics Inc., Regeneron Pharmaceuticals Inc., Editas Medicine Inc., Evox Therapeutics Ltd., PepGen Ltd.

What Geographic Markets Are Powering Growth in the Oligonucleotide Therapy Market?
North America was the largest region in the oligonucleotide therapy market in 2024. The regions covered in the oligonucleotide therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=3398

This Report Supports:
1. Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2. Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3. Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4. Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas - +1 310-496-7795 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.